Status:
COMPLETED
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Lead Sponsor:
Daiichi Sankyo
Conditions:
Tenosynovial Giant Cell Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy in previously treated participants with tenosynovial giant cell tumor (TGCT).
Detailed Description
This multicenter study in previously pexidartinib-treated participants with TGCT will provide the Investigators and participants the option at Screening to either continue pexidartinib treatment (Trea...
Eligibility Criteria
Inclusion
- Currently enrolled and on pexidartinib treatment in one of the following studies: Study PLX108-10 (ENLIVEN), Study PLX108-01, Study PL3397-A-A103 or Study PL3397-A-U126.
- Willing and able to complete the PROMIS Physical Function Scale and EQ-5D-5L throughout the study.
- Willing and able to provide written informed consent prior to any study-related procedures and to comply with all study requirements.
- Females of reproductive potential must have a negative urine pregnancy test at Screening/Baseline (to be confirmed by a serum pregnancy test taken on the last treatment visit of their prior study). They are advised to use an effective, non-hormonal method of contraception during treatment with pexidartinib and for 1 month after the last dose. Males with female partners of reproductive potential should be advised to use an effective method of contraception during treatment with pexidartinib and for 1 month after the last dose. Female partners of male patients should concurrently use effective contraceptive methods (hormonal or non-hormonal).
- Note: A female is considered of reproductive potential following menarche and until becoming postmenopausal (no menstrual period for a minimum of 12 months) unless permanently sterile (undergone a hysterectomy, bilateral salpingectomy or bilateral oophorectomy) with a confirmed by follicle stimulating hormone (FSH) test level \>40 mIU/mL.
- Male participants must not freeze or donate sperm starting at Screening and throughout the study period, and for at least 5 half-lives or 1 month after the final study drug administration, whichever is longer. Female participants must not donate, or retrieve for their own use, ova from the time of Screening and throughout the study treatment period, and for at least 1 month or 5 half-lives after the final study drug administration, whichever is longer.
Exclusion
- Participant has a clinically significant abnormality identified by the Investigator at Screening on physical examination, laboratory tests, or electrocardiogram (ECG) which, in the judgement of the Investigator, would preclude the participant's safe completion of the study.
- Exposure to another investigational drug or current participation in other therapeutic investigational procedures, besides pexidartinib studies, within 1 month prior to start of study treatment. Any known contraindication to treatment with, including hypersensitivity to, the study drug(s) or excipients in pexidartinib.
Key Trial Info
Start Date :
October 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 7 2023
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04526704
Start Date
October 20 2020
End Date
July 7 2023
Last Update
December 30 2024
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Honor Health
Scottsdale, Arizona, United States, 85258
2
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
3
Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136
4
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215